94 related articles for article (PubMed ID: 11361889)
21. Protease inhibitors shine in triple combinations.
AIDS Alert; 1996 Mar; 11(3):31-2. PubMed ID: 11363243
[TBL] [Abstract][Full Text] [Related]
22. To AIDS and back with Norvir, D4T, 3TC and nutritional therapies. An interview with Michael Golk.
Golk M
Posit Health News; 1998; (No 16):5-7. PubMed ID: 11365018
[TBL] [Abstract][Full Text] [Related]
23. Research study of combination AIDS therapies underway.
AIDS Patient Care STDS; 1996 Apr; 10(2):132. PubMed ID: 11361697
[No Abstract] [Full Text] [Related]
24. Preliminary data on 141W94 reported.
AIDS Patient Care STDS; 1998 Jan; 12(1):65-6. PubMed ID: 11361894
[No Abstract] [Full Text] [Related]
25. Drug combination shows benefits for AIDS patients with history of taking AZT.
AIDS Patient Care STDS; 1996 Jun; 10(3):185-6. PubMed ID: 11361628
[No Abstract] [Full Text] [Related]
26. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
27. [Experiences with antiretroviral combination therapy].
Justesen US; Mygind LH; Pedersen SS; Pedersen C
Ugeskr Laeger; 1999 Mar; 161(12):1747-51. PubMed ID: 10210973
[TBL] [Abstract][Full Text] [Related]
28. Head-to-head study of protease inhibitors.
AIDS Patient Care STDS; 1998 Jan; 12(1):63-4. PubMed ID: 11361890
[No Abstract] [Full Text] [Related]
29. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients.
Cato A; Qian J; Hsu A; Levy B; Leonard J; Granneman R
Antimicrob Agents Chemother; 1998 Jul; 42(7):1788-93. PubMed ID: 9661022
[TBL] [Abstract][Full Text] [Related]
30. Kaletra lower-strength pediatric tablet approved in Europe.
AIDS Patient Care STDS; 2008 May; 22(5):437-8. PubMed ID: 18521973
[No Abstract] [Full Text] [Related]
31. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
32. Assessing efficacy by measuring CD(4) counts and quality of life of AIDS patients treated with ritonavir, AZT and 3TC.
Neto JL; Siciliano RF
Braz J Infect Dis; 2000 Aug; 4(4):173-82. PubMed ID: 11008221
[TBL] [Abstract][Full Text] [Related]
33. [Meeting of the Pediatric Work Group AIDS in Germany (PAAD) on May 8-9, 1998 in Frankfurt/Main].
Funk M
Klin Padiatr; 1999; 211(2):96-7. PubMed ID: 10407820
[No Abstract] [Full Text] [Related]
34. Phase III results presented on amprenavir triple combination.
AIDS Patient Care STDS; 1998 Dec; 12(12):941-2. PubMed ID: 11362070
[No Abstract] [Full Text] [Related]
35. Switching HIV-1 protease inhibitor therapy: which? When? And why?
Guardiola JM; Domingo P; Vazquez G
Arch Intern Med; 1999 Jan; 159(2):194-5. PubMed ID: 9927104
[No Abstract] [Full Text] [Related]
36. Update on antivirals.
PI Perspect; 1996 Sep; (No 19):7-9. PubMed ID: 11363906
[TBL] [Abstract][Full Text] [Related]
37. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Ait-Khaled M; Rakik A; Griffin P; Cutrell A; Fischl MA; Clumeck N; Greenberg SB; Rubio R; Peters BS; Pulido F; Gould J; Pearce G; Spreen W; Tisdale M; Lafon S;
Antivir Ther; 2002 Mar; 7(1):43-51. PubMed ID: 12008787
[TBL] [Abstract][Full Text] [Related]
38. [HIV: less resistance due to combined treatment].
Dtsch Med Wochenschr; 1996 Dec; 121(49):A47-8. PubMed ID: 8998914
[No Abstract] [Full Text] [Related]
39. Pregnancy danger.
Posit Aware; 1998; 9(5):18. PubMed ID: 11365886
[TBL] [Abstract][Full Text] [Related]
40. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
